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Abstract
Long-term changes in dopaminergic signaling are thought to underlie the pathophysiology of a number of psychiatric
disorders. Several conditions are associated with cognitive deficits such as disturbances in attention processes and learning
and memory, suggesting that persistent changes in dopaminergic signaling may alter neural mechanisms underlying these
processes. Dopamine transporter knockout (DAT-KO) mice exhibit a persistent five-fold increase in extracellular dopamine
levels. Here, we demonstrate that DAT-KO mice display lower hippocampal theta oscillation frequencies during baseline
periods of waking and rapid-eye movement sleep. These altered theta oscillations are not reversed via treatment with the
antidopaminergic agent haloperidol. Thus, we propose that persistent hyperdopaminergia, together with secondary
alterations in other neuromodulatory systems, results in lower frequency activity in neural systems responsible for various
cognitive processes.
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Introduction
Hippocampal theta oscillations (HTO) are prominent local field
potential oscillations generated by the brain, and occur within
the 4–9 Hz frequency range [1,2]. These oscillations are
especially prominent during periods of exploration and rapid-
eye-movement (REM) sleep [1–3], and play a critical role in
high-end cognitive processes such as spatial learning, fear
conditioning, and attention [4–6]. Many studies have been
aimed at elucidating the neuromodulatory systems responsible
for the generation and modulation of HTO’s; however, the
central methodologies employed across these studies have
classically focused on using pharmacologic agents to acutely
manipulate signaling within neuromodulatory systems [7–10].
Given the growing body of evidence suggesting that persistent
changes in neuromodulatory systems underlie the behavioral and
cognitive deficits observed across several neuropsychiatric
disorders [11–15], there is increased demand for understanding
how persistent changes in neuromodulatory systems alter these
brain oscillations [16].
The neurotransmitter dopamine (DA) is critically involved in
regulating neural processes responsible for complex movements,
emotions, attention, and arousal and sleep states [17–19]. Acute
administration of psychostimulants or direct DA receptor agonists
generate high frequency HTO’s in rats [20]. Importantly, these
agents modulate extracellular dopamine levels [21]. Despite the
clear effects of acute hyperdopaminergia on HTO’s, influences of
persistent hyperdopaminergia on HTO’s are obscure. This is an
important omission given that long-term changes in DA signaling
are thought to underlie, at least in part, the pathophysiology of
attention-deficit-hyperactivity disorder (ADHD) [11], schizophre-
nia [12] and bipolar disorder [13].
DA transporter (DAT) knockout (KO) mice lack the gene
encoding the plasma membrane transporter that regulates spatial
and temporal DA signaling at the synapse. Due to loss of the DAT,
these mutants exhibit a persistent 5-fold increase in extracellular
DA levels [21], and show locomotor hyperactivity, deficits in
sensorimotor gating, and impaired learning and memory [22–25].
Here we demonstrate that DAT-KO mice display significantly
lower HTO frequencies during baseline waking and REM sleep
periods. Additionally, we show that the altered HTO’s observed in
DAT-KO mice are not corrected via treatment with haloperidol.
Thus, we propose that persistent hyperdopaminergia and its
associated secondary changes in other neuromodulatory systems
PLoS ONE | www.plosone.org 1 April 2009 | Volume 4 | Issue 4 | e5238ultimately results in lower frequency activity in neural systems
responsible for high-end cognitive processes.
Materials and Methods
Animals
The WT and DAT-KO littermates were generated from
heterozygotes that had been backcrossed over twenty generations
onto the C57BL/6J background. Mice were housed three-five/
cage and maintained in a humidity- and temperature-controlled
room with standard lab chow and water available ad libitum.
Thirteen male WT mice and eleven DAT-KO mice were
separated into individual cages, and surgically implanted with
electrodes and electromyographic (EMG) wires. Recording
experiments were conducted following a one week recovery. All
studies were conducted with approved protocols from the Duke
University Institutional Animal Care and Use Committee and
were in accordance with the NIH guidelines for the Care and Use
of Laboratory Animals.
Surgery
Adult mice (20–35 weeks) were anesthetized with a Ketamine
(100 mg/kg)/Xylazine (10 mg/kg) solution, placed in a stereotaxic
device, and ground screws were secured to the cranium. Tungsten
microwire array electrodes were implanted through a small cranial
window into the dorsal hippocampus (stereotaxic coordinates:
22.3 mm anterior posterior, 1.6 mm mediolateral and 1.8 mm
dorsoventral from bregma), and anchored to ground screws using
dental acrylic. Tungsten EMG wires were placed into the trapezius
muscle, and the skin was closed using surgical sutures.
Experimental set-up for electrophysiological recordings
All experiments were conducted in a recording chamber,
consisting of an empty cage bottom (11.5 in67i n 64.5 in) marked
into six equal sections. Gross locomotor activity was determined by
the number of section crosses normalized to total wake time during
the recording period.
Data acquisition
Local field potentials (LFPs) were preamplified (5006), filtered
(0.3–400 Hz), and digitized at 500 Hz using a Digital Acquisition
card (National Instruments, Austin, TX) and a Multi-Neuron
Acquisition Processor (Plexon, Dallas, TX). Behaviors were
recorded with a video cassette recorder. Video images were
loaded onto a cassette recorder and synchronized with the neural
recordings using a millisecond-precision timer.
Behavioral state and total theta power identification
Behavioral states were identified by combining two-dimensional
state map and EMG cluster analysis as previously described [19].
Briefly, the state map generated cluster separation based on the
high amplitude theta (4–9 Hz) and gamma (33–55 Hz) oscillations
characteristic of REM sleep, the absence of gamma oscillations
and the high amplitude delta (1–4 Hz) characteristic of SWS, and
the high amplitude gamma oscillations and theta oscillations
characteristic of waking. Minor scoring errors typically occurred in
differentiating REM sleep from active exploration, thus EMG
analysis was used to identify periods of atonia consistent with
REM sleep, and combined with the two-dimensional state map
cluster scoring method for all sleep experiments conducted in this
study. LFP’s were simultaneously recorded from 8 implanted
electrodes, and the LFP which produced the best cluster
separation was used for all experiments presented here. Impor-
tantly, our method did not control for the layer of hippocampus in
which the recording electrode used for analysis was located. This is
an important confound because the amplitude of theta oscillations
change as a function of depth in hippocampus [2]. For instance,
our experiments in which five WT mice were recorded in the
novel environment, habituated environment, and during REM
sleep reveal a high coefficient of variance (CV) in the maximum
theta power measured across animals (CV=0.49, 0.52, and 0.52,
for recordings in the novel environment, habituated environment,
and during REM sleep, respectively). Additionally, our experi-
ments in five DAT-KO mice reveal a similarly high coefficient of
variation (CV) in the maximum theta power measured across
animals (CV=0.56, 0.49, and 0.55, for recordings in the novel
environment, habituated environment, and during REM sleep,
respectively). However, we found that by normalizing the maximum
mean theta power measured during the waking periods by that
recorded during REM sleep for each animals, we were able to
reduce the CV measured across animals by up to 80% (CV=0.09/
0.15, and 0.09/0.11 for theta power measured in the novel cage/home
cage inWTandDAT-KO mice, respectively).Importantly,themean
power spectrum observed during REM sleep remained unchanged
when DAT-KO and WT mice were treated with drugs, as well as
during 12-hour experimental recordings conducted in their home
cage [19]. These results indicate that the peak theta power observed
during REM sleep can be utilized effectively as the baseline variable
to correct for changes in theta wave amplitude recorded from
different depths of hippocampus.
Determination of peak theta frequency
First, all data segments with amplitude saturation were
discarded from the dataset (2% of the total data per mouse).
Using Matlab (MathWorks, Natick, MA), a sliding window Fourier
transform was applied to the LFP signal using a 2 sec window with
a 1 sec step. The Fourier transform parameters were chosen to
allow for a frequency resolution of 0.5 Hz. Subsequently, LFP
power spectra were then averaged across each period of interest (at
least 2 total minutes for REM sleep, 10 total minutes for baseline
waking, and 10 total minutes for active exploration), and the
frequency at which the maximum spectral power occurred in the
theta frequency (4–9 Hz) range was identified. For experiments
examining REM sleep, we also determined the peak theta
frequency using Fourier transform parameters chosen to allow
for a frequency resolution of 0.25 Hz. The instantaneous phase
values of theta oscillations shift throughout the depth of
hippocampus; however, oscillations are phase locked across layers
[2]. Thus, unlike measurements of theta power, the peak theta
frequency is independent of which layer the recording electrode is
located.
Drug treatments during electrophysiological
measurements
A 0.3 mg/kg (i.p.) dose of haloperidol (HAL) was chosen
because it attenuates behavioral hyperactivity in novelty-exposed
DAT-KO animals to a degree similar to that observed in
untreated habituated WT mice [19]. d-Amphetamine (AMPH)
was given at 3.0 mg/kg (i.p.) because it increased extracellular DA
levels and induced behavioral hyperactivity in WT mice to similar
degrees as those observed in untreated DAT-KO mice [26]. The
serotonin selective reuptake inhibitor Fluoxetine (FLU) was given
at 20 mg/kg (i.p.).
Statistics
The data are presented as means and standard errors of the
mean. The electrophysiological data were analyzed by two-way
Persistent DA Alters HTOs
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isons within genotype, and Student t-test for comparisons between
genotypes. The behavioral data were analyzed by two-way
ANOVA, followed by Student t-test for single comparisons. In
all cases p,0.05 was considered significant.
Results
Hyperdopaminergic mice show alterations in baseline
hippocampal theta oscillations
DAT-KO mice display a period of marked behavioral
hyperactivity lasting up to four hours after introduction to a novel
environment [19,24]. Thus, in order to examine the effects of
persistent hyperdopaminergia on baseline HTOs, DAT-KO and
WT mice were habituated to the recording chamber for eight
hours and subsequently subjected to two-hour continuous
electrophysiological and behavioral recordings. Despite WT and
DAT-KO mice showing similar behavioral profiles, total delta
power (normalized delta power: WT mice: 3.660.5, DAT-KO
mice: 4.360.4; n=5; p.0.05) and total theta power (see Fig. 1A
and 2E), DAT-KO mice displayed lower peak HTO frequencies
during the baseline waking period than WT mice (WT mice:
7.160.2 Hz, DAT-KO mice: 5.760.2 Hz; Fig. 1A,). In order to
ensure that the lower HTO frequencies observed in DAT-KO
mice were truly due to changes associated with persistent
hyperdopaminergia, and not simply behavioral differences that
were too small to measure with our scoring technique, we
implored a second behavioral scoring method based on our video
data and EMG recordings. Using this method for five animals in
each group, we identified the minimal EMG activity associated
with movement and limited our analysis to include only one
second intervals where mice displayed EMG activity below the
movement threshold. Importantly, DAT-KO mice continued to
display lower peak HTO frequencies than WT mice when the
analysis was restricted to periods when both groups were
completely still (WT mice: 6.960.3 Hz, DAT-KO mice:
5.760.4 Hz; n=5 per group). Thus, the lower HTO frequencies
observed in behaviorally habituated DAT-KO mice were indeed
due to changes associated with persistent hyperdopaminergia and
not simply small differences in behavioral profiles. This result was
particularly interesting because acute treatments with DA agonists
has been shown to induce high frequency HTO’s [9,20,27]. Next,
we investigated if these changes in HTO’s were present across all
baseline behavioral states observed in DAT-KO mice by analyzing
HTO spectral patters observed across DAT-KO and WT mice
during REM sleep. Our results indicate that DAT-KO mice show
lower peak HTO frequencies than WT mice during REM sleep
(WT mice: 7.260.1 Hz, DAT-KO mice: 6.560.2 Hz; Fig. 1B).
Importantly, similar results were also obtained when the frequency
resolution was increased from 0.5 Hz to 0.25 Hz. This demon-
strates that lower frequency HTO’s are present across both
baseline waking and sleeping periods in DAT-KO mice.
In order to determine if persistent hyperdopaminergia altered
HTO activity during waking periods characterized by increased
exploratory behavior, we conducted two-hour electrophysiological
and behavioral recordings in DAT-KO and WT mice that were
not habituated to the recording chamber. Interestingly, despite the
marked behavioral hyperactivity displayed by the DAT-KO mice
following exposure to the novel recording chamber, peak HTO
frequencies were comparable to those observed in novelty-exposed
WT mice (WT mice: 8.060.1 Hz, DAT-KO mice: 8.060.1 Hz,
Fig. 1C). Peak HTO frequencies were, however, higher in novelty
exposed WT and DAT-KO mice than those observed during the
baseline waking period. Novelty exposure also increased theta
power in DAT-KO mice, but not WT mice (Fig. 1C, see Fig. 2E).
Importantly, exposure to novelty does not change dopaminergic
tone in WT or DAT-KO mice [24]. Therefore, as WT and DAT-
KO mice display similar peak HTO frequencies following
exposure to novelty, while dopaminergic tone remains constant,
our results suggest that persistent hyperdopaminergia does not
decrease the peak frequency of HTO’s in DAT-KO mice across
all behavioral states.
Overall, our findings suggest that persistent hyperdopaminergia
generates compensatory network changes which decrease the peak
frequency of HTO’s during baseline behavioral periods. Con-
versely, our results also raise the possibility that hyperdopami-
nergia lowers peak HTO frequencies across all behavioral states,
and that the similar peak HTO frequencies observed in novelty
exposed WT and DAT-KO mice is a result of the higher
behavioral profiles exhibited by DAT-KO animals.
Acute Dopamine D2 receptor transmission involved in
novelty-induced increases in HTO frequencies
Next, we investigated the molecular mechanisms underlying the
changes in HTO’s observed in DAT-KO mice. DAT-KO mice
and WT mice were treated with the D2 dopamine receptor
antagonist haloperidol 0.3 mg/kg, i.p. (HAL), and two-hour
electrophysiological and behavioral recordings were conducted.
HAL attenuated behavioral hyperactivity (see Fig. 2F) and novelty-
induced peak HTO frequency increases in both WT (vehicle:
8.060.1 Hz, HAL: 6.560.2 Hz; Fig. 2A) and DAT-KO mice
(vehicle: 8.060.1 Hz, HAL: 6.360.1 Hz; Fig. 2B). Taken
together, these findings demonstrate that acute dopaminergic
transmission, via the D2 dopamine receptor, plays a critical role in
the induction of high frequency HTO’s in DAT-KO mice
following novelty exposure. Interestingly, HAL did not reduce
total theta power in DAT-KO mice (see Fig. 2E), suggesting that
alterations in other neuromodulatory systems may mediate the
novelty induced increases in theta power observed in these
animals.
Next, we investigated the effect of HAL on the altered HTO’s
observed during baseline behavioral periods in DAT-KO mice.
Systemic administration of pharmacological agents induced
behavioral hyperactivity in habituated DAT-KO mice, thus we
employed a modified experimental paradigm. Firstly, behavioral
and electrophysiological recordings were extended to four hours in
WT and DAT-KO mice treated with HAL. Secondly, analysis was
limited to periods of REM sleep occurring within this four hour
window. Because the four hour recording period was within the
half-life of HAL in mice [28], and the effect of external behavioral
influences on HTO’s is relatively limited during REM sleep, this
experimental paradigm allowed us quantify the effect of HAL on
the altered HTO frequencies observed in habituated DAT-KO
mice. Our results showed that DAT-KO mice treated with HAL
displayed lower peak HTO frequencies during REM sleep that
WT mice treated with HAL (WT mice: 7.560.3 Hz, DAT-KO
mice: 6.660.1 Hz, p,0.02). These results indicate that HAL does
not attenuate the altered HTO frequencies observed in DAT-KO
mice during baseline behavioral periods.
DA independent modulation of HTOs
Next, we conducted our recording protocol in WT mice treated
with the psychostimulant d-amphetamine 3.0 mg/kg, i.p.
(AMPH). Dopamine agonists have been shown to increase peak
HTO frequencies [20]; thus, we predicted that treatment with
AMPT would increase peak HTO frequencies in WT animals.
Surprisingly, our results showed that WT mice treated with d-
amphetamine displayed peak HTO frequencies that were
Persistent DA Alters HTOs
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vehicle (WT: 6.760.1 Hz; tstat1,8=3.9, p,0.005, see Fig. 2C).
We also found that AMPH increased total theta power in WT
mice (see Fig. 2E). While AMPH causes a profound increase in
dopamine release in WT animals at the dose used for this
experiment (3.0 mg/kg), it has also been shown to increase
serotonin levels [23]. Thus, we set out to investigate if the lower
peak HTO frequencies observed in WT mice treated with AMPH
resulted from acute hyperdopaminergia or secondary changes in
other neuromodulatory systems.
Firstly, WT animals were treated with both HAL and AMPH,
and electrophysiological data was collected during the 2-hour
recording period. Our results showed that AMPH significantly
lowered peak HTO frequencies in WT animals treated with HAL
(WT/HAL and AMPH: 5.960.2 Hz; tstat1,8=2.9, p,0.02),
indicting that HAL did not attenuate the peak HTO frequency
lowering effect of AMPH. Secondly, we treated DAT-KO mice
with d-amphetamine. DAT-KO mice lack a key target of AMPH,
the DA transporter [21], and thus the drug exerts a calming effect
via serotonergic mechanisms [23,24]. In DAT-KO mice, AMPH
significantly lowered peak HTO frequencies (vehicle: 8.060.1 Hz,
AMPH: 5.360.4 Hz; Fig. 2D). Upon further analysis, we also
found that DAT-KO mice treated with AMPH displayed peak
HTO frequencies that were even lower than those observed in
DAT-KO treated with HAL (N-K10=4.00). Incidentally, AMPH
attenuated novelty-induced hyperactivity in DAT-KO mice to a
lesser degree than HAL (HAL: 0.460.1, AMPH: 1.760.3,
tstat1,8=3.9, p,0.005). Moreover, in contrast to HAL, treatment
with AMPH also significantly attenuated novelty induced increases
in total theta power in DAT-KO mice (see Fig. 2E). Finally, we
treated WT animals with the serotonin selective reuptake inhibitor
fluoxetine (FLU, 20 mg/kg i.p.). Our results showed that FLU
significantly lowered the peak frequency of HTO’s in WT mice
(WT mice/Saline: 8.060.1 Hz, WT mice/FLU: 6.660.3 Hz,
n=5, p,0.05), suggesting that increases in serotonergic tone were
sufficient to reduced HTO frequencies.
Taken together, these results suggest that the lower peak HTO
frequencies observed in WT animals treated with AMPH are likely
due to secondary changes in serotonergic neuromodulatory
systems, and not acute hyperdopaminergia.
Discussion
Our findings demonstrate that DAT-KO mice display
decreased hippocampal theta oscillations frequencies during
baseline waking periods and REM sleep. Incidentally, these
findings are in contrast to studies that have shown that acute
treatment with DA agonists generates increases in HTO
frequencies [9,20,27]. Thus, our findings reveal for the first time
that persistent hyperdopaminergia lowers baseline hippocampal
theta oscillation frequencies.
HTO’s are prominent LFP’s generated by the brain, and occur
in the 4–9 Hz frequency range. These oscillations are especially
prominent during waking periods of increased attention and rapid-
eye-movement (REM) sleep [1,2]. HTO’s control the timing of
activity across neuronal populations in hippocampus, prefrontal
cortex, and amygdala and coordinate gamma oscillatory activity
[4,5,29]. Gamma oscillations are a major indicator of cortical
processing and a critical determinant of long term potentiation
and depression [30,31]. Thus, even small changes in baseline
HTO frequencies are likely to alter neural activity across large
distributed brain networks, ultimately generating deficits in gross
behavioral processes. Importantly, baseline HTO frequencies
observed during quiet waking and REM sleep have been shown
to be predictive of learning rates across rodents [32].
HTO’s are also highly correlated with behaviors such as
changes in posture or limb position, walking, head movements,
and rearing [33]. We have previously shown that the enhanced
theta power observed in DAT-KO mice following novelty
exposure is not simply due to the increased locomotor activity
observed in these animals [19]. While peak HTO frequencies
increase in WT and DAT-KO mice following novelty-induced
hyperactivity as well, the changes in baseline HTO’s observed in
DAT-KO mice are unlikely to be due to gross locomotor
behavioral changes. Firstly, despite demonstrating similar behav-
ioral profiles during the baseline waking period, DAT-KO mice
display significantly lower the peak frequency of HTO’s.
Importantly, this difference persists even when our analysis is
restricted to intervals when animals are completely still. Moreover,
DAT-KO mice display lower peak HTO frequencies than WT
mice during periods of REM sleep where both genotypes of mice
are behaviorally inactive. WT and DAT-KO also display similar
peak HTO frequencies following novelty exposure, though DAT-
KO mice experience a significant increase in gross locomotor
activity. Collectively, these findings suggest that the altered HTO
frequencies observed in DAT-KO mice HTO’s can be dissociated
from changes in gross locomotor behavioral activity. Secondly,
though treatment with AMPH induces gross locomotor hyperac-
tivity in WT animals, it lowered peak theta oscillations frequencies.
Moreover, treatment with d-amphetamine caused greater de-
creases in peak HTO frequencies in DAT-KO mice than
treatment with haloperidol, though haloperidol attenuated behav-
ioral hyperactivity to a greater degree. Taken together, these
findings provide compelling evidence that persistent hyperdopa-
minergia generates changes in HTO’s that are locomotor activity
independent, resulting in a decrease in the peak frequency of
HTO’s during baseline periods.
Figure 1. Altered HTOs in hyperdopaminergic mice. Mean hippocampal LFP power distributions were calculated in the 2–12 Hz range for each
mouse across the behavioral periods of interest. The images depict normalized power spectral distributions averaged across animals within
genotype. Two way ANOVA of HTO frequency found the main effects of genotype [F1,49=21.66, p,0.01] and condition [F4,49=82.82, p,0.01], as well
as the genotype by condition interaction [F4,49=9.96, p,0.01] to be significant. Post-hoc tests revealed that DAT-KO mice display lower hippocampal
theta oscillation (HTO) frequencies than WT mice during (A) baseline waking (p,0.01) and (B) REM sleep periods (p=0.011), but not (C) waking
periods immediately following novelty exposure (p=0.35). Locomotor activity measured during the A) habituated and C) novelty exposed waking
states are depicted in insets, and behavioral statistics are shown in Fig. 2F. One way ANOVA found significant effects when mice were exposed to a
novel environment for both DAT-KO [F4,24=54.47, p,0.01] and WT mice [F4,24=31.19, p,0.001]. Newman-Keuls tests showed that peak HTO
frequencies increased with novelty exposure for both genotypes (DAT-KO: N-K20=3.92, WT: N-K20=2.35). Error bars represent S.E.M for normalized
theta power determined for each frequency across animals within a genotype; n=11 for both genotypes. Two way ANOVA of total theta power
found the main effects of genotype [F1,39=15.21, p,0.01] and condition [F3,39=4.55, p,0.01], as well as the genotype by wake-state interaction
[F3,39=6.46, p,0.01] to be significant. Post-hoc tests revealed that total theta power was not different between DAT-KO and WT mice during the
baseline waking period (p.0.1); however, it was significantly higher in DAT-KO mice than WT mice following novelty exposure (p,0.01). One way
ANOVA’s found significant effects of condition for DAT-KO [F3,19=8.22, p,0.01] but not WT mice [F3,19=2.05, p.0.05]. Newman-Keuls tests showed
that novelty exposure increased total theta power in DAT-KO (N-K10=4.66).
doi:10.1371/journal.pone.0005238.g001
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calculated in the 2–12 Hz range for each mouse across the drug treatment of interest. The images depict normalized power spectral distributions
averaged across animals within genotype and drug treatment. Treatment with haloperidol 0.3 mg/kg (HAL) significantly attenuated novelty induced
peak HTO frequencies increases in both (A) WT (N-K20=3.39) and (B) DAT-KO (N-K20=3.29) mice, and treatment with d-amphetamine 3.0 mg/kg
(AMPH) attenuated novelty induced peak HTO frequency increases in both (C) WT (N-K20=3.06) and (D) DAT-KO (N-K20=4.42) mice. (E) Novelty and
psychoactive drug effects on total theta power. Treatment with AMPH, but not HAL, potentiated novelty-induced theta power in WT mice (AMPH: N-
K20=5.01, HAL: N-K20=5.01). Novelty-induced theta power was attenuated by treatment with AMPH, and unaffected by treatment with HAL in DAT-
KO mice (AMPH: N-K20=5.66, and HAL: N-K20=4.66, respectively). (F) Novelty and psychoactive drug effects on locomotor activity. WT and DAT-KO
mice displayed similar behavioral profiles during baseline periods (tstat1,8=0.96, p=0.36). Novelty exposure induced behavioral hyperactivity in DAT-
KO mice (tstat1,8=2.39, p,0.05), compared to novelty exposed WT mice. HAL attenuated locomotor activity in both genotypes. AMPH attenuated
locomotor activity in DAT-KO mice, and potentiated locomotor activity in WT mice. Error bars represent S.E.M for recordings within a genotype.
#=p,0.05; compared to animals within genotype during the baseline period. *=p,0.05; compared to animals within genotype during the novelty
exposed; n=5 for all groups.
doi:10.1371/journal.pone.0005238.g002
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responsible for complex movements and emotions [18]. Conse-
quently, altered central dopaminergic neurotransmission has been
implicated in several neurological and psychiatric disorders such as
schizophrenia, Parkinson’s disease, and ADHD. While recent
evidence demonstrates that transient over-expression of striatal D2
dopamine receptors during development results in deficits in
working memory [34], and that increases in tonic dopaminergic
stimulation generate global deficits in learning and memory [35],
it is unclear how persistent changes in dopaminergic transmission
alter neural activity in brain areas that mediate cognitive
processes. Our results demonstrate that persistent hyperdopami-
nergia generates a baseline slowing of hippocampal neural
networks. Additionally, we show that while administration of the
classic antidopaminergic agent HAL attenuates behavioral hyper-
activity in DAT-KO mice, it does not correct the reduced peak
HTO frequencies observed during baseline behavioral periods.
Moreover, we show that treatment with AMPH attenuates
novelty-induced behavioral hyperactivity, and reduces the peak
frequency of HTO’s and HTO power in persistently hyperdopa-
minergic mutants. DAT-KO mice lack a key target of AMPH, the
DA transporter [21]; thus, it is likely that AMPH exerts a calming
effect via serotonergic mechanisms [23,24]. Recent evidence has
shown that the stress cascade modulates central serotonergic
signaling [36], and that disruption of serotonergic signaling
mechanisms increase HTO power [16].
Taken together with our findings, this suggests that the baseline
HTO alterations observed in DAT-KO mice may be mediated via
changes in the serotonergic neuromodulatory system, and that the
behavioral hyperactivity, and peak theta frequency and power
increases observed in novelty exposed DAT-KO mice are likely
mediated in-part by stress induced disruption of serotonergic
mechanisms. Indeed, DAT-KO mice display profound alterations
in serotonin homeostasis that may underlie the changes in baseline
neuron-oscillatory properties presented here [25]. Thus, we
propose that persistent hyperdopaminergia induces compensatory
changes in serotonergic systems, in order to regulate information
flow through circuits responsible for locomotor behavior [37],
which result in slower processing rates in hippocampal neural
networks. Overall, the present results show that DAT-KO mice
display decreased HTO frequencies, and demonstrate the central
role of persistent hyperdopaminergia in modulating baseline
hippocampal neural oscillatory activity.
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